SCHEMBL6663891

SCHEMBL6663891

COC(=O)Cc1ccccc1N1CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.51
DRD2 P14416 2/20 0.50
DRD3 P35462 2/20 0.50
HTR1A P08908 2/20 0.49
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
DRD4 P21917 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPBWR1 P48145 1/20 0.47
MCHR1 Q99705 1/20 0.47
NOTUM Q6P988 1/20 0.47
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
ADRA2C P18825 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 2/20 0.44
BRD4 O60885 2/20 0.44
BRPF1 P55201 2/20 0.44
BRD9 Q9H8M2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6641495 0.86 ALDH1A1 (0.50) NCF1MEN1KMT2ATSHRHTT
SCHEMBL6640315 0.83 NCF1 (0.55) NCF1DRD2DRD3HTR1AHTR2A
SCHEMBL8260725 0.83 GAA (0.48) MEN1KMT2AGAAGFERPOLB
SCHEMBL5160166 0.82 NCF1 (0.57) NCF1DRD2DRD3HTR1AHTR2A
SCHEMBL26655902 0.81 KDM4E (0.50) MEN1KMT2ANPBWR1MCHR1TSHR
SCHEMBL30664591 0.81 KDM4E (0.50) MEN1KMT2ANPBWR1MCHR1TSHR
SCHEMBL30664596 0.81 KDM4E (0.50) MEN1KMT2ANPBWR1MCHR1TSHR
Hydrochloric Acid SCHEMBL6662184 0.79 NCF1 (0.55) NCF1DRD2DRD3HTR1AHTR2A
SCHEMBL8361520 0.79 DRD2 (0.72) NCF1DRD2DRD3HTR1AHTR2A
SCHEMBL1307890 0.77 DRD2 (0.59) DRD2DRD3HTR1AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 NCF1 659/4885DRD2 4464/4885DRD3 4368/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 NCF1 696/4885DRD2 4497/4885DRD3 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.